Back to search results

Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia

Abroad (travel likely)RecruitingPHASE1

Conditions

Leukemia · Myeloid Leukemia · Monocytic Leukemia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • University of Colorado Hospital, Aurora, Colorado, United States

    Contact: Study coordinator (Derek Schatz) · DEREK.SCHATZ@CUANSCHUTZ.EDU · (720) 848-0628
    Contact: Principal Investigator (Andrew Kent, MD, PhD)
    Maria Amaya, MD (Sub-investigator)
    Mathew Angelos, MD (Sub-investigator)
    Steven Bair, MD (Sub-investigator)
    Jonathan Gutman, MD (Sub-investigator)
    Brad Haverkos, MD (Sub-investigator)
    Jagar Jasem, MD (Sub-investigator)
    Manali Kamdar, MD (Sub-investigator)
    Ajay Major, MD (Sub-investigator)
    Christine McMahon, MD (Sub-investigator)
    Jorge Monge Urrea, MD (Sub-investigator)
    Daniel Pollyea, MD (Sub-investigator)
    Marc Schwartz, MD (Sub-investigator)
    Daniel Sherbenou, MD (Sub-investigator)
Study leads

  • Andrew Kent, MD, PhD

    Principal Investigator

    University of Colorado, Denver

View source on ClinicalTrials.gov(opens in a new tab)